Evidence map›Paper›PMID 41011753›Full record

ArticlePathogens (Basel, Switzerland)2025

Evaluation of the PreTect HPV-Proofer E6/E7 mRNA Assay for the Detection of Precancerous Cervical Lesions in the Greek Female Population.

Athanasia Kafasi, Vassiliki C Pitiriga, Nikolaos Spanakis, Nikolaos Vlachos, Nikolaos Thomakos, Stamatios Stournaras, Athanasios Tsakris, Georgios Kaparos

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Athanasia KafasiDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Vassiliki C PitirigaDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-1951-8489
Nikolaos SpanakisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Nikolaos Vlachos2nd Department of Obstetrics and Gynecology, Areteion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Nikolaos ThomakosDivision of Gynecologic Oncology, 1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Stamatios StournarasMaternity and Gynecology Clinic, IASO Hospital, 15123 Athens, Greece.
Athanasios TsakrisDepartment of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0003-0656-4715
Georgios KaparosDepartment of Microbiology, Areteion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer remains a significant public health concern, ranking as the 10th most common cancer among women in Greece. Current screening programs primarily rely on cytology and HPV DNA testing; however, their positive predictive value (PPV) for detecting high-grade cervical intraepithelial neoplasia (CIN2+) remains limited. This study aimed to compare the clinical performance of the HPV mRNA test with that of the HPV DNA test, focusing on their PPV for detecting CIN1+ lesions in a cohort of Greek women. A total of 114 women undergoing routine cervical cancer screening were tested using an HPV DNA assay (detecting 41 HPV types), Pap smear, and were referred for colposcopy and biopsy when indicated. Among them, 29 women aged 18 to 65 years (mean age: 35.1 ± 10.8 years) who tested positive for one or more of the five high-risk HPV types (16, 18, 31, 33, 45) were further assessed using the PreTect HPV-Proofer

Indexed as

Oncogene Proteins, ViralPapillomaviridaePapillomavirus InfectionsPrecancerous ConditionsRNA, MessengerUterine Cervical DysplasiaUterine Cervical NeoplasmsAdolescentAdultAgedEarly Detection of CancerFemaleGreeceHumansMiddle AgedPredictive Value of TestsOncogene Proteins, ViralRNA, MessengerRNA, Viralcervical cancer screeningE6/E7 oncogenesHPV mRNA testingPreTect HPV-proofer

Identifiers

PMID41011753
PMCPMC12472212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.